Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 3/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413571 | 1.00 | GRM5 (0.51) | GRM5TDP1FADS1PGRKCNH2 | |
| SCHEMBL10244382 | 1.00 | GRM5 (0.51) | GRM5TDP1FADS1PGRKCNH2 | |
| SCHEMBL13394570 | 1.00 | GRM5 (0.51) | GRM5TDP1FADS1PGRKCNH2 | |
| SCHEMBL11099684 | 0.84 | MAPT (0.42) | GRM5 | |
| SCHEMBL11099686 | 0.84 | MAPT (0.42) | GRM5 | |
| SCHEMBL9671149 | 0.84 | MAPT (0.42) | GRM5 | |
| SCHEMBL338191 | 0.83 | GRM5 (0.49) | GRM5 | |
| SCHEMBL6374631 | 0.83 | GRM5 (0.49) | GRM5 | |
| SCHEMBL4291 | 0.83 | GRM5 (0.49) | GRM5 | |
| SCHEMBL8192290 | 0.83 | GRM5 (0.49) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | GRM5 4799/4885TDP1 1006/4885FADS1 206/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | GRM5 4799/4885TDP1 1006/4885FADS1 206/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | GRM5 4799/4885TDP1 1006/4885FADS1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.